Logo image of OCS

OCULIS HOLDING AG (OCS) Stock Overview

NASDAQ:OCS - CH1242303498 - Common Stock

16.145 USD
-0.21 (-1.25%)
Last: 8/29/2025, 3:03:09 PM

OCS Key Statistics, Chart & Performance

Key Statistics
52 Week High23.08
52 Week Low11.56
Market Cap840.51M
Shares52.06M
Float48.76M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.91
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO03-03 2023-03-03
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


OCS short term performance overview.The bars show the price performance of OCS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15

OCS long term performance overview.The bars show the price performance of OCS in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of OCS is 16.145 USD. In the past month the price decreased by -7.31%. In the past year, price increased by 36.25%.

OCULIS HOLDING AG / OCS Daily stock chart

OCS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.21 691.11B
JNJ JOHNSON & JOHNSON 17.72 426.70B
NVO NOVO-NORDISK A/S-SPONS ADR 14.41 250.41B
AZN ASTRAZENECA PLC-SPONS ADR 17.98 247.57B
NVS NOVARTIS AG-SPONSORED ADR 14.28 244.60B
MRK MERCK & CO. INC. 10.9 209.71B
PFE PFIZER INC 7.29 140.52B
SNY SANOFI-ADR 11.2 121.05B
BMY BRISTOL-MYERS SQUIBB CO 6.98 95.68B
GSK GSK PLC-SPON ADR 8.73 79.67B
ZTS ZOETIS INC 25.08 69.13B
TAK TAKEDA PHARMACEUTIC-SP ADR 49.88 47.26B

About OCS

Company Profile

OCS logo image Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Company Info

OCULIS HOLDING AG

Bahnhofstrasse 7

Zug ZUG CH

Employees: 49

OCS Company Website

OCS Investor Relations

Phone: 41588100182

OCULIS HOLDING AG / OCS FAQ

What is the stock price of OCULIS HOLDING AG today?

The current stock price of OCS is 16.145 USD. The price decreased by -1.25% in the last trading session.


What is the ticker symbol for OCULIS HOLDING AG stock?

The exchange symbol of OCULIS HOLDING AG is OCS and it is listed on the Nasdaq exchange.


On which exchange is OCS stock listed?

OCS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for OCULIS HOLDING AG stock?

12 analysts have analysed OCS and the average price target is 37.01 USD. This implies a price increase of 129.24% is expected in the next year compared to the current price of 16.145. Check the OCULIS HOLDING AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OCULIS HOLDING AG worth?

OCULIS HOLDING AG (OCS) has a market capitalization of 840.51M USD. This makes OCS a Small Cap stock.


How many employees does OCULIS HOLDING AG have?

OCULIS HOLDING AG (OCS) currently has 49 employees.


What are the support and resistance levels for OCULIS HOLDING AG (OCS) stock?

OCULIS HOLDING AG (OCS) has a support level at 14.31 and a resistance level at 17.54. Check the full technical report for a detailed analysis of OCS support and resistance levels.


Is OCULIS HOLDING AG (OCS) expected to grow?

The Revenue of OCULIS HOLDING AG (OCS) is expected to decline by -19.84% in the next year. Check the estimates tab for more information on the OCS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy OCULIS HOLDING AG (OCS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OCULIS HOLDING AG (OCS) stock pay dividends?

OCS does not pay a dividend.


What is the Price/Earnings (PE) ratio of OCULIS HOLDING AG (OCS)?

OCULIS HOLDING AG (OCS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.91).


What is the Short Interest ratio of OCULIS HOLDING AG (OCS) stock?

The outstanding short interest for OCULIS HOLDING AG (OCS) is 0.02% of its float. Check the ownership tab for more information on the OCS short interest.


OCS Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to OCS. When comparing the yearly performance of all stocks, OCS turns out to be only a medium performer in the overall market: it outperformed 65.24% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

OCS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to OCS. The financial health of OCS is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OCS Financial Highlights

Over the last trailing twelve months OCS reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS decreased by -31.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -50.4%
ROE -63.27%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%3.92%
Sales Q2Q%6.53%
EPS 1Y (TTM)-31.64%
Revenue 1Y (TTM)N/A

OCS Forecast & Estimates

12 analysts have analysed OCS and the average price target is 37.01 USD. This implies a price increase of 129.24% is expected in the next year compared to the current price of 16.145.

For the next year, analysts expect an EPS growth of 5.71% and a revenue growth -19.84% for OCS


Analysts
Analysts88.33
Price Target37.01 (129.24%)
EPS Next Y5.71%
Revenue Next Year-19.84%

OCS Ownership

Ownership
Inst Owners31.05%
Ins Owners3.06%
Short Float %0.02%
Short Ratio0.56